Cargando…

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy

The tumor microenvironment restricts the function and survival of various immune cells by up-regulating inhibitory immune checkpoints, and participates in the immune escape of tumors. The development of immunotherapies targeting immune checkpoints, such as programmed cell death receptor 1 antibody a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Daijun, Gu, Yanmei, Yan, Xin, Huo, Chengdong, Wang, Guan, Zhao, Yang, Teng, Muzhou, Li, Yumin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005749/ https://www.ncbi.nlm.nih.gov/pubmed/35433470 http://dx.doi.org/10.3389/fonc.2022.844260

Ejemplares similares

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
por: Murakami, Daisuke, et al.
Publicado: (2022)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway
por: Ma, Bin, et al.
Publicado: (2019)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy
por: Ducoin, Kathleen, et al.
Publicado: (2022)

Organoids: Construction and Application in Gastric Cancer
por: Huo, Chengdong, et al.
Publicado: (2023)

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis
por: Ozmadenci, Duygu, et al.
Publicado: (2022)

Blocking TIGIT/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer
por: Liu, Lu, et al.
Publicado: (2022)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

Construction of targeted (10)B delivery agents and their uptake in gastric and pancreatic cancer cells
por: Wang, Song, et al.
Publicado: (2023)

Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma
por: Duan, Xiangguo, et al.
Publicado: (2019)

Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
por: Ma, Long, et al.
Publicado: (2022)

Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2022)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
por: Jin, Hyung-seung, et al.
Publicado: (2021)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
por: Matsuo, Tomohei, et al.
Publicado: (2022)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer
por: Cabioglu, Neslihan, et al.
Publicado: (2023)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

4-1BB: A promising target for cancer immunotherapy
por: Kim, Alyssa Min Jung, et al.
Publicado: (2022)

A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
por: Luo, Cong, et al.
Publicado: (2021)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways
por: Liu, Lu, et al.
Publicado: (2021)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)

Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers
por: Ai, Huihan, et al.
Publicado: (2023)

A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer
por: Li, Yuansen, et al.
Publicado: (2022)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
por: Chen, Can, et al.
Publicado: (2022)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
por: Szereday, Laszlo, et al.
Publicado: (2021)

Metastasis Pattern and Survival Analysis in Primary Small Bowel Adenocarcinoma: A SEER-Based Study
por: Gu, Yanmei, et al.
Publicado: (2021)

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
por: Meng, Fanqiao, et al.
Publicado: (2020)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells
por: Forster, Stefan, et al.
Publicado: (2020)

TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment
por: Jantz-Naeem, Nouria, et al.
Publicado: (2023)

GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers
por: Sathe, Anuja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_prr9fcd98hkqoujpf5ep8bjoch